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ABSTRACT
MicroRNAs (miRNAs) are small regulatory RNAs tar-
geting multiple effectors of cell homeostasis and
development, whose malfunctions are associated
with major pathologies such as cancer. Herein we
show that GAM/ZFp/ZNF512B works within an intri-
cate gene regulatory network involving cell-cycle
regulators, TGFb effectors and oncogenic miRNAs
of the miR-17-92 cluster. Thus, GAM impairs
the transcriptional activation of the miR-17-92
promoter by c-Myc, downregulates miR-17-92
miRNAs differentially, and limits the activation of
genes responsive to TGFb canonical pathway. In
contrast, TGFb decreases GAM transcripts levels
while differentially upregulating miR-17-92
miRNAs. In turn, miR-17, miR-20a and miR-92a-1
target GAM transcripts, thus establishing a
feedback autoregulatory loop. GAM transcripts
are also targeted by miRNAs of the let-7 family.
GAM downregulates Drosha, the main effector of
miRNA maturation in the nucleus, and interacts
with it in a RNA-dependent manner. Finally, GAM
modulates the levels of E2F1 and Ras, and increases
apoptosis while reducing cell proliferation. We
propose that GAM represents a new kind of verte-
brate regulator aimed at balancing the opposite
effects of regulators of cell homeostasis by
increasing the robustness of gene circuitries
controlling cell proliferation, differentiation and
development.
INTRODUCTION
MicroRNAs (miRNAs) have been implicated in the regu-
lation of a number of fundamental processes, including
muscle, cardiac, neural and lymphocyte development, or
the regulation of both the innate and adaptive immune
responses (1,2). MiRNAs originate from primary tran-
scripts (pri-miRNAs) converted in the nucleus into precur-
sor miRNAs (pre-miRNAs) by the RNase III Drosha,
associated with DGCR8 to form the small microprocessor
complex (3). Pre-miRNAs are then exported in the cyto-
plasm where the miRNA hairpin is cleaved by the RNase
III Dicer within the RISC loading complex. The guide
strand, which corresponds to the mature miRNA, is
then incorporated into the RISC complex (3). MiRNAs
and their transcriptional regulators usually form
autoregulatory loops aimed at controlling their respective
levels (4).
MiRNAs participate in gene regulatory networks whose
molecular malfunctions are associated with major
pathologies such as cancer (5–7). Thus, the miR-17-92
cluster on chromosome 13, which appeared with the ver-
tebrates, contains six miRNAs (miR-17, -18a, -19a, -20a,
-19b-1 and -92a-1). The miR-17-92 cluster is ampliﬁed and
overexpressed in B-cell lymphomas and solid tumors such
as breast or small-cell lung cancers (5), where it may
enhance oncogenesis by potentially targeting E2F1,
p21/CDKN1A and BCL2L11/BIM (8). However, there is
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miR-17-92 miRNAs might be advantageous for cancer
cells in certain settings. Indeed, loss-of-heterozygosity at
the 13q31.3 locus has been observed in multiple tumor
types, and a genome-wide analysis of copy number alter-
ations in cancer revealed that the miR-17-92 cluster was
deleted in 16.5% of ovarian cancers, 21.9% of breast
cancers and 20% of melanomas (9). The transcription of
the miR-17-92 cluster is controlled by c-Myc and E2F
factors (10–13). Interestingly, miR-17 and miR-20a target
E2F1, while miR-20a also targets E2F2 and E2F3 (10,12).
Two ortholog clusters are found on chromosomes 7
(miR-106b-93-25) and X (miR-106a-18b-20b-19b-2-92a-
2-363), respectively. In contrast to miR-17-92 miRNAs
that appeared late in evolution, let-7 miRNAs belong to
a family of early developmental regulators well conserved
during evolution (14). The let-7 gene family expanded
from one member in nematods to more than 10 in
mammals. In C. elegans, let-7 works as a master regulator
of temporal patterning by controlling the transition from
undifferentiated, proliferating stem cells to differentiated,
quiescent cells (14). In human, let-7 miRNAs are frequent-
ly downregulated in cancers like lung, colon or other solid
tumors (5), and are therefore considered as tumor suppres-
sor miRNAs in these types of cancers. In particular, let-7
miRNAs target oncogenes of the Ras family (15) and
c-Myc, and their expression in colon tumors results in
reduced levels of both Ras and c-Myc (16).
GAM/ZFp/ZNF512B, a vertebrate-speciﬁc zinc-ﬁnger
factor, was recently identiﬁed as a potential developmental
regulator whose isoform shifts correlated with the main
stages of skin and heart morphogenesis in chicken (17).
In human, GAM transcripts are present in all tissues and
cell types tested so far. Although GAM may possibly bind
TC- and/or AG-rich DNA sequences (17), none of its
target genes has been identiﬁed to date, and its functions
remain elusive. Interestingly, GAM 30-UTR (untranslated
region) contains target sequences for  150 miRNAs,
several of whose, including miR-17-92 and let-7
miRNAs, have been implicated in the regulation of devel-
opment and/or have been described either as oncomirs or
tumor suppressor miRNAs. Given that miRNAs can po-
tentially target tens to hundreds of different transcripts,
we hypothesized that GAM and at least some of the
miRNAs targeting its 30-UTR may form regulatory gene
circuitries aimed at regulating cell homeostasis through
their combined effects on key regulators of cell prolifer-
ation. Here, we present the ﬁrst evidence that GAM
indeed may work as a molecular sensor potentially
aimed at maintaining cell homeostasis by affecting the
levels of regulators of cell homeostasis such as E2F1 and
Ras, by modulating the levels of miR-17-92 miRNAs, by
regulating the levels of and interacting with Drosha, and
by interfering with TGFb signaling.
MATERIALS AND METHODS
Cell culture and transfection
HEK-293, HepG2 and MCF7 were transfected using
Lipofectamine 2000 (Invitrogen). K562 cells were
electroporated using the AMAXA kit. Whenever needed,
cells were mock-treated or stimulated 34h after transfec-
tion with TGFb (100ng/ml, from R&D) for 14h. Stealth
oligonucleotides targeting GAM (siGAM), Drosha
(siDrosha) and c-Myc (siMyc) were from Invitrogen.
Preparation of constructs
The human GAM cDNA was ampliﬁed by PCR from a
mix of human cDNAs purchased from Clontech. The
miR-17-92 cluster promoter, the whole miR-17-92 cluster
sequence and the 30-UTR of GAM were cloned by PCR
from genomic DNA extracted from HEK-293 cells. GAM
30-UTR was cloned downstream of the luciferase gene in
the XbaI site of the pGL3-Control vector (Promega) or
downstream of GAM encoding sequence in the
pCMV-HA vector. The whole sequence of the miR-17-92
cluster was inserted into the pCMV vector. The c-Myc
expression vector was from Invitrogen. The sequences of
the oligonucleotides used for cloning are available upon
request.
Luciferase assays
HEK-293 cells plated in 12-well plates were transfected
with 0.4mg of either the empty pGL3-Control vector or
constructs containing miRNA target sites, the indicated
pre-miRNAs (100nM ﬁnal, Ambion) and 20ng of
Renilla luciferase control vector (pRL-TK from
Promega). Assays were performed 24h after transfection
using the Dual Luciferase Reporter Assay system
(Promega). Fireﬂy luciferase activity was normalized to
Renilla luciferase activity. As a control, we used the
pre-miR Precursor Molecule-Negative Control #1
(referred to here as control RNA) from Ambion. TGFb
signaling in HepG2 cells was tested in sixplicates in 24-well
plates using the Cignal SMAD Reporter Assay Kit
(Luciferase) from Super Array Bioscience Corporation.
This kit is designed to monitor the activity of the canon-
ical TGFb-induced signal transduction pathway, i.e. to
give a measure of the rate of SMAD2 and/or SMAD3
nuclear transcriptional activity in conjunction with
SMAD4 on a reporter construct containing a functional
SMAD-binding site.
Western blots
Cells transfected and/or treated as needed were lysed 24h
or 48h after transfection. Anti-p21/CDKN1A and
-a-tubulin antibodies were from Cell Signaling
Technology. Anti-c-Myc and anti-Drosha antibodies
were from Abcam. Anti-E2F1, anti-pan-Ras, anti-GAM/
ZNF512B, anti-Dicer, anti-DGCR8 and anti b-Actin
antibodies were from Santacruz.
Apoptosis and proliferation assays
Apoptosis and proliferation assays were conducted using
the Mitochondrial Permeability Transition Detection Kit
from Immunochemistry Technologies and the XTT Cell
Proliferation Kit from Cayman, respectively, according to
the manufacturer’s instructions.
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RNAs extracted with TRIzol (Invitrogen) were subse-
quently subjected to DNase digestion (Turbo-DNase-
Ambion). GAM and Drosha quantitative real-time PCRs
(qRT–PCRs) were conducted after reverse transcription
with the commercial ready-to-use primers/probe mix of
Applied Biosystems. Values were normalized using
GAPDH or  -actin. MiRNA qRT–PCR were performed
using TaqMan MicroRNA Assays (Applied Biosystems).
Values were normalized using RNU-44. Real-time PCRs
were run in triplicates from three different cDNAs. As
miR-92a-1 and -92a-2 sequences are 100% identical, they
are collectively referred to as miR-92a in qRT–PCR
experiments.
RNase-protection assays
Sense oligonucleotides used for the preparation of
double-strand DNA templates for T7 RNA polymerase
were as follows: miR-17:5 0-CAAAGTGCTTACAGTGC
AGGTAG(T)13; miR-18a:5 0-TAAGGTGCATCTAGTG
CAGATAG(T)13; miR-20a:5 0-TAAAGTGCTTATAGT
GCAGGTAG(T)13; RNAs containing miR-92a1:5 0-GTT
TCTGTATGGTATTGCACTTGTCCCGGCCTGTTGA
GTTTG (the position of miR-92a-1 is given by bolded
underlined letters); U6snRNA:5 0-CGATACAGAGAAG
ATTAGCATGGCCCCTGCGCAAGG. Antisense RNA
probes were synthesized using the mirVana miRNA Probe
Construction Kit from Ambion in the presence of
a
32P-CTP (3000Ci/mmol) and subsequently puriﬁed
onto a denaturing TBE-Urea 15% polyacrylamide gel.
The resulting antisense probes are 10-nt longer than the
protected fragments. RNAs extracted with TRIzol
(Invitrogen) or yeast tRNA were incubated overnight at
42 C in the presence of 8 10
4 cpm of the antisense RNA
probes in the hybridization buffer provided by the
mirVana miRNA Detection Kit from Ambion.
RNase-digestion were done for 30min at 37 C using a
1/50 dilution of the RNAse A/RNase T1 solution
provided by the same kit. Samples were subsequently
separated on a denaturing TBE-Urea 15% polyacrylamide
gel in the presence of radiolabeled Ambion Decade
Markers (not shown on the ﬁgures due to the necessity
to overexpose the gels to allow for the detection of the
miR-17-92 miRNAs). Gels were then subjected to auto-
radiography at  80 C in the presence of an amplifying
screen.
Promoter activity studies
MCF7 cells were transfected with the empty pGL3-Basic
(Promega) or a construct in pGL3-Basic containing differ-
ent fragments of the miR-17-92 cluster promoter inserted
upstream of the Luciferase gene, together with the
pRL-TK vector for internal control, along with either
pCMV-HA, pCMV-HA-GAM, pCMV-c-Myc, or their
combinations, or with a Control RNA or with either
siGAM and/or siMyc. The Fireﬂy luciferase activity was
measured 48h post-transfection and normalized to Renilla
luciferase activity.
Protein interaction assays
HEK-293 cells were transfected with either an empty
control vector or a construct expressing the tagged
factor of interest. Cells were lysed 24h after transfection
in 1ml of NP-40 lysis buffer supplemented with 0.5mM
ZnCl2. Supernatants were incubated overnight with
anti-HA (Covance) or anti-Flag (Sigma) antibody.
HA- or Flag-expressing lysates were further incubated
with protein A/G sepharose (Amersham). The bound
proteins were subjected to three washes of 30min
each and then eluted by boiling for 5min in the loading
buffer. Whenever needed, RNase-digestion was con-
ducted at 4 C for 30min before addition of the anti-HA
antibody using RNase A from Qiagen (200mg/ml).
Immunocomplexes were analyzed by SDS–PAGE electro-
phoresis followed by immunoblotting with anti-Drosha,
anti-Flag or anti-HA.
Statistical analysis and quantiﬁcation
Comparisons with the respective controls were done using
the Student’s t-test, and P-values are provided in the ﬁgure
legends. Band quantiﬁcation was done using the Adobe
Photoshop software. The relative intensities of the bands
of interest, prealably normalized to either a tubulin
(western blots) or U6snRNA (RNase-protection assays),
are given under each panel in percent of the respective
control sample.
RESULTS
GAM transcripts are targeted by miR-17-92 and let-7
miRNAs
In silico analyzes using the TargetScan software
(http://www.targetscan.org) showed that the 30-UTR of
human GAM contains conserved putative target sites
for  150 different miRNAs, including three sites
for miR-17-92 miRNAs (one for miR-92a-1 and two for
miR-17/20a) or their respective orthologs and three for
let-7 miRNAs (Figure 1A and Supplementary Tables S1
and S2). In order to validate these target sites, the 30-UTR
of human GAM was inserted in both orientations down-
stream of the luciferase gene in the pGL3-Control vector,
providing us with sense (Luc-1S) and antisense (Luc-1AS)
constructs collectively referred to as Luc-1 on Figure 1A.
Three shorter clones (Luc-2, -3 and -4) were prepared simi-
larly. Transfecting HEK-293 cells with pre-miR-17,- 20a
and -92a-1 or their respective orthologs pre-miR-106b, -93
and -25 signiﬁcantly decreased the expression of Luc-1S
while remaining without effects on Luc-1AS (Figure 1B).
Similar results were obtained with two let-7 pre-miRNAs,
namely pre-let-7a and -let-7d (Figure 1B). In contrast,
miR-155 remained without effects, in accordance with
the fact that GAM 30-UTR contains no miR-155 target
site. The expression of Luc-2S was also reduced by
either pre-miR-92a-1 or -25, but neither by pre-miR-17
nor -miR-20a, due to the lack of their common target
sites (Figure 1C). Luc-2S was also targeted by let-7d
(Figure 1D). Furthermore, miR-17, -20a, -106b and -93
targeted Luc-3S and/or Luc-4S, the latter being also
Nucleic Acids Research, 2010,Vol.38, No. 21 7675targeted by let-7d (Supplementary Figure S1A and B).
Finally, mutating the different target sites
(Supplementary Tables S1 and S2) abolished the effects
of the different pre-miRNAs (Figure 1D).
To determine if the targeting of GAM 30-UTR by
the above miRNAs would also reduce GAM protein
accumulation, a human GAM cDNA encoding the
same protein as GenBank AB033022 sequence except for
a conservative proline to leucine change was inserted
upstream of the different parts of GAM 30-UTR in the
pCMV-HA expression vector (Figure 1A). As expected,
the levels of HA-GAM-1 and HA-GAM-2 were reduced
by either pre-miR-17, -20a, -92a-1 or their respective
orthologs (Supplementary Figure S2A), and the
downregulation of HA-GAM-4 by pre-miR-20a was
impaired by mutating the corresponding miR-17/20a
target site (Supplementary Figure S2B). Finally, an
anti-GAM antibody allowed us to deﬁnitely ascertain
the downregulating effects of pre-miR-17, -20a, -92a-1
and -let-7d (Figure 1E and F, respectively). In contrast,
as one would expect, transfecting HEK-293 cells with
either antisense miR-17, -20a, -92a or let-7d inhibitory
RNAs increased GAM levels (Figure 1E and F), which
shows that both miR-17-92 and let-7 miRNAs regulate
GAM expression in vivo. Collectively, these results give
strong evidence that these two families of miRNAs
should actually target the 30-UTR of GAM transcripts
in cell.
Figure 1. GAM transcripts are direct targets of miR-17-92 and let-7 miRNAs. (A) Schematic representation of GAM 30-UTR constructs in
pGL3-Control (Luc-1, -2, -3 and -4) and pCMV-HA (HA-GAM-1, -2, -3 and -4). Conserved putative target sites for miR-17/20a (17,20),
miR-92a-1 (92) and let-7 (L7) miRNAs are indicated. The positions of the 50- and 30-limits of the inserts with respect to GAM 30-UTR are indicated
over the lines, and their respective lengths are given in bp below the lines. (B–D) Luciferase assays were done with Luc-1 to Luc-4 as indicated, both
in sense (S) and antisense (AS) orientation. Mutations in constructs used in D are given in Supplementary Tables S1 (miR-17-92 miRNA target sites)
and S2 (let-7 miRNA target sites). Bars show the ratios of the Fireﬂy luciferase (normalized to Renilla luciferase) activity measured following
transfection with the indicated pre-miRNAs to that obtained following transfection with the pre-miR Control for the same construct. Values
represent the mean±SD (n=4). (B and C) *P<0.001, signiﬁcantly different from pre-miR Control. (D) *P<0.005, signiﬁcantly different from
wild type construct. (E and F) Endogenous GAM levels in HEK-293 cells transfected with either a pre-miR-Control, the indicated pre-miRNAs or
antisense inhibitory RNAs to miR-17, miR-20a or miR-92a (17-I, 20-I and 92-I, respectively) were determined by western blotting.
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As E2F1 was previously shown to be targeted by both
miR-17 and miR-20a (10,12), the blots from the middle
and right panels of Supplementary Figure S2A were
reprobed with an anti-E2F1 antibody. Expectedly,
pre-miR-20a and -106b downregulated E2F1 and
HA-GAM-1. Given that the two corresponding tran-
scripts contain target sites for miR-17/20a, this provides
good evidence that the effects of pre-miR-17-92 miRNAs
on HA-GAM levels were due to the production of fully
functional miRNAs (Supplementary Figure S2A). In
contrast, while downregulating HA-GAM-1 and
HA-GAM-2, pre-miR-92a-1 and its ortholog pre-miR-25
increased E2F1 levels, suggesting that they may normally
work to limit certain effects of miR-17 and miR-20a, spe-
cially those related to the regulation of E2F1 expression.
Given the opposite effects of miR-17, -20a and -92a-1 on
E2F1 levels despite their common downregulating effects
on endogenous GAM (Supplementary Figure S2A and
Figure 1E, respectively), we then checked if increasing
GAM levels may have any consequences on E2F1 accu-
mulation. Overexpressing HA-GAM-2 reduced E2F1 level
by  40% (Figure 2A). In contrast, siRNAs directed
against GAM transcripts (hereafter referred to
as siGAM), which signiﬁcantly decreased both GAM
transcript and GAM protein levels (Supplementary
Figure S3A–D), increased E2F1 levels by  50%
(Figure 5D). This suggests that GAM may somehow inter-
fere with the effects of E2F1 on cell proliferation. To de-
termine whether GAM may also affect other regulators of
cell homeostasis, the blot of Figure 2A was reprobed with
a pan-Ras antibody. Namely, Ras proteins function as
intracellular switches in signal transduction cascades
and, due to their ability to modulate transcription, they
control cell growth and proliferation as well as other
aspects of cell biology including senescence/cell-cycle
arrest, differentiation and survival (18). Furthermore,
like GAM transcripts, Ras transcripts represent validated
targets of let-7 miRNAs (15). In sharp contrast with E2F1,
overexpressing HA-GAM-2 increased Ras level  9-fold
(Figure 2A), while siGAM showed opposite effects
(Supplementary Figure S4). Of note, while HA-GAM-4
and Ras 30-UTRs do not contain any miR-92 target site,
cotransfecting HEK-293 cells with pre-miR-92a-1 and
HA-GAM-4 reduced the upregulation of Ras by GAM
by  50% (Figure 2B). This prompted us to look for the
effects of miR-92a-1 on Ras expression. As shown in
Figure 2C, overexpressing miR-92a-1 slightly decreased
Ras levels. In contrast, transfecting HEK-293 cells with
a miR-92a antisense inhibitory RNA increased Ras accu-
mulation. Thus, miR-92a-1 can downregulate Ras by tar-
geting either endogenous GAM transcripts or other
transcripts encoding positive regulators of Ras.
Finally, as mentioned earlier, miR-17-92 and let-7
miRNAs are respectively considered as oncogenes and
tumor suppressor genes, due to their opposite effects on
cell proliferation, apoptosis and more generally on cell
homeostasis. GAM transcripts being a target of these
two functionally opposite groups of miRNAs, and
Figure 2. GAM modulates E2F1 and Ras levels, increases cell apop-
tosis and reduces cell proliferation. (A) HEK-293 cells were transfected
with either pCMV-HA or HA-GAM-2. GAM effects on E2F1 and Ras
were analyzed by western blotting. (B) HEK-293 cells were transfected
with either pCMV-HA or HA-GAM-4 along with a control RNA or
pre-miR-92a-1. GAM effects on Ras were analyzed by western blotting.
(C) Ras levels in HEK-293 cells transfected with either a pre-miR-
control, pre-miR-92a-1 or a miR-92a antisense inhibitory RNA (92-I)
were determined by western blotting. (D) HEK-293 cells transfected as
indicated were assayed 24h later for apoptosis or proliferation. Values
represent the mean±SD (n=3). # and ##, Signiﬁcantly different from
apoptosis control,
#P=0.063,
##P<0.005. * and **, Signiﬁcantly dif-
ferent from proliferation control, *P<0.02, **P<0.005.
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that it might act as a molecular sensor aimed at maintain-
ing cell homeostasis. Indeed, overexpressing GAM
increased cell apoptosis while reducing cell proliferation,
with siGAM having opposite effects (Figure 2D).
GAM decreases the expression of miR-17-92
miRNAs differentially
Aimed at regulating the expression of their target genes,
miRNAs tend to build feedback regulatory loops with
their regulators (4). Thus, as GAM transcripts were
targeted by miR-17-92 miRNAs, and given that GAM
and miR-92a-1 had opposite effects on both E2F1
and Ras expression (Supplementary Figure S2A and
Figure 2A–C, respectively), we therefore hypothesized
that GAM in turn may regulate miR-17-92 miRNA
levels. Indeed, overexpressing GAM in HEK-293
(Figure 3A) or in K562 lymphoid cells (Supplementary
Figure S5) decreased the levels of miR-17-92 miRNAs.
In contrast, the levels of these miRNAs increased follow-
ing the transfection of HEK-293 (Figure 3B), HepG2
(Figure 6B) or MCF-7 breast cancer cells
(Supplementary Figure S6) with siGAM. Finally, GAM
overexpression also decreased the levels of miR-17, -20a
and -92a in HEK-293 cells transfected with Clu-81,a
3837-bp expression construct containing the whole
miR-17-92 cluster (Figure 3C). This indicates that GAM
generally works to impair any surge of miR-17-92 miRNA
levels. It also suggests that both the upregulation of Ras
and the downregulation of E2F1 by GAM (see hereabove)
might be due at least in part to GAM downregulating
effects on miR-92a-1 levels.
Of note, and although qRT–PCR assays cannot dis-
criminate between miR-92a-1 and miR-92a-2, the relative
Figure 3. GAM downregulates miR-17-92 miRNAs. (A and B). The relative levels of miR-17-92 miRNAs in HEK-293 cells transfected with either
the empty pCMV-HA vector or pCMV-HA-GAM (A), or with either a control RNA or siGAM (B), were determined by qRT–PCR. Values represent
the mean±SD (n=3). (A) * and **, Signiﬁcantly different from empty control vector, *P<0.004, **P<0.0004. (B) *P<0.005, signiﬁcantly
different from control RNA. (C) HEK-293 cells were transfected with either a control pCMV-HA/Control RNA mix or a construct in the
pCMV vector expressing the whole miR-17-92 cluster (Clu-81) in combination with either a pCMV-HA/Control RNA mix, a pCMV-HA-GAM/
Control RNA mix, or a pCMV-HA/siDrosha mix. Clu-81 contains a 3837-bp insert bearing the whole miR-17-92 cluster sequence (787bp) plus
216-bp upstream of the ﬁrst nucleotide of pre-miR-17 and 2834-bp downstream of the last nucleotide of pre-miR-92a-1. The relative levels of the
indicated miRNAs were determined by qRT–PCR. Values represent the mean±SD (n=3). *P<0.01, signiﬁcantly different from control mix.
(D) HEK-293 cells were transfected with Clu-81 along with either the empty pCMV-HA vector or pCMV-HA-GAM. The relative levels of RNAs
containing unprocessed miR-92a-1 (42-nt long protected band) were determined by RNase-protection assays using 2mg total RNA per assay. The
efﬁciency of RNase digestion was assessed in parallel following the incubation of each probe with the same amount of yeast tRNAs (two left lanes).
‘-RNase’ controls correspond to a 15-fold dilution of the undigested sample. The relative intensities of the protected fragments, calculated using the
U6snRNA as an internal control, are given in percent of the pCMV-HA control. Nd, non-digested, Ns, non-speciﬁc.
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the cluster were generally higher than those with a more 50
position (Figures 3A and B, 6A and B and Supplementary
Figures S5 and 6). These results indicate that miR-17-92
miRNAs are processed with a differential efﬁciency from
transcripts produced from the miR-17-92 cluster host
gene, i.e. MIRHG1 or C13orf25. This was further con-
ﬁrmed by the fact that transfecting HEK-293 cells with
Clu-81 also lead to the differential expression of miR-17,
-20a and -92a (Figure 3C), which suggests that HEK-293
cells may contain limiting amounts of unidentiﬁed factors
required for the processing of each of the miR-17-92
miRNAs.
Furthermore, in the four cell lines under study, GAM
and/or siGAM affected the levels of the tested miR-17-92
miRNAs differentially (Figures 3A–C, 6A and B and
Supplementary Figures S5 and 6), suggesting that GAM
may somehow affect their processing. Unfortunately,
nothing is known about the processing of miR-17-92
miRNAs beyond the fact that the production of
miR-18a requires the presence of hnRNPA1 (19,20). It is
also not known whether transcripts starting at either the
TSS1 (transcription start site 1, i.e. the TSS of the
C13orf25 host gene) (13), the TSS2 (21), or both TSSs
may function as miR-17-92 primary RNAs, nor if any of
these transcripts allows the simultaneous production of
the six mature miR-17-92 miRNAs, or not. Gaining de-
ﬁnitive answers to these questions will obviously require a
number of experiments and is well beyond the scope of
this article. Nevertheless, to gain further evidence of GAM
effects on miR-17-92 miRNAs processing, we used
RNase-protection assays to follow the levels of RNAs
containing unprocessed miR-92a-1 in HEK-293 cells
transfected with Clu-81 along with either an empty
pCMV-HA control vector or a construct overexpressing
GAM. Indeed, GAM overexpression increased the relative
levels of RNAs containing unprocessed miR-92a-1 by
 35% (Figure 3D). Given the facts that GAM is located
in the nucleus [(17) and Tili et al., unpublished results] and
that GAM overexpression did not change the levels of
Dicer, which further processes the pre-miRNAs in the
cytoplasm (Supplementary Figure S7), the result of
Figure 3D gives an independent indication that GAM
may somehow decrease, directly or indirectly, the process-
ing of miR-17-92 primary transcripts in the nucleus.
GAM impairs the activation of the miR-17-92 cluster
by c-Myc
The expression of miRNAs can be regulated both tran-
scriptionally and post-transcriptionally. The above results
suggested that GAM downregulating effects on the ex-
pression of miR-17-92 miRNAs come at least in part
from post-transcriptional effects. To determine if the
downregulation of miR-17-92 miRNAs by GAM may
also arise from effects on the miR-17-92 cluster expression,
we used ﬁve promoter constructs containing miR-17-92
TSS2 (21) (Figure 4A). Four of them, but Clu-5, contain
the Myc-binding site previously shown to be bound by
c-Myc to transactivate the miR-17-92 cluster (10). Clu-1,
Clu-2 and Clu-3 were generated by fusing Clu-4 to more
upstream sequences containing the TSS1 (13). These con-
structs were tested in MCF7 cells, where both miR-17-92
miRNAs (22) and c-Myc (23) are well expressed. A high
level of luciferase activity was produced from Clu-1 and
Clu-2, but the lack of a 123-bp fragment containing E2F-
binding sites 1 and 2 (12) in Clu-3 decreased the luciferase
activity by  75% (Figure 4B). This indicates that this
123-bp fragment is required for a robust expression of
the cluster, in agreement with the fact that E2F factors
have been shown to bind E2F-binding sites 1–4 and
activate the transcription from the TSS1 (12,13). The
activity of Clu-4 was still lower, and that of Clu-5
similar to the empty control vector. Overexpressing
GAM decreased four times the activation of Clu-1 and
Clu-2, while remaining without signiﬁcant effects on
Clu-3 (Figure 4B). In contrast, it increased the expression
of Clu-4 and Clu-5, which was probably due to off-target
effects allowing the activation of the TSS2 through modi-
ﬁcations of the levels of some of the transcriptional acti-
vators and repressors whose target sequences are known
to be present in the pGL3-Basic vector. Regardless, these
results suggest that GAM can decrease the transcriptional
activation of the C13orf25 host gene from the TSS1.
In agreement with previously published results (10),
overexpressing c-Myc lead to a further activation of
Clu-1 to Clu-4 (Figure 4C). The highest levels of expres-
sion were again obtained with Clu-1 and Clu-2, indicating
that transcription factors other than c-Myc, whose target
sequences should be present both within and upstream the
123-bp fragment missing in Clu-3, were working along
c-Myc to activate the expression of the reporter con-
structs. In contrast, siRNAs directed against c-Myc tran-
scripts (siMyc) reduced the levels of expression of Clu-1
and Clu-2 to that of the empty pGL3-Basic vector,
showing that the presence of c-Myc activity is mandatory
for the activation of the miR-17-92 cluster promoter from
the TSS1, at least in the conditions of the experiment
(Figure 4D). Coexpressing GAM along with c-Myc
decreased the activating effects of c-Myc on Clu-1 and
Clu-2 (Figure 4C). Of note, neither GAM overexpression
nor siGAM affected c-Myc protein levels (Supplementary
Figure S8), indicating that GAM activity interferes,
directly or indirectly, with the transcriptional activation
of the miR-17-92 cluster by c-Myc. However, GAM
overexpression did not reduce the activating effects of
c-Myc on Clu-3, Clu-4 and Clu-5 (Figure 4C), suggesting
that GAM effects might not be directed toward c-Myc
itself but rather toward some of the unidentiﬁed transcrip-
tional activators acting on the 123-bp fragment deleted in
Clu-3 and/or on sequences located upstream of Clu-2.T o
determine if GAM repressing effects were dependent on
E2F sites 1 and 2, we then used constructs derived from
Clu-2 whose either E2F site 2 (Clu-2-ME2) or both E2F
sites 1 and 2 (Clu-2-ME1,2) had been mutated
(Supplementary Figure S9). These mutations did not
change the levels of expression of Clu-2, indicating that
the effects of E2F factors on this construct rather take
place through E2F sites 3 and/or 4. Of note, these muta-
tions also did not impair GAM repressing activity,
indicating that GAM opposes the activating effects of
some factors working on this 123-bp fragment either
Nucleic Acids Research, 2010,Vol.38, No. 21 7679beside or along E2F factors. Finally, the lack of effects of
siGAM showed that endogenous GAM activity is
normally too low to impair the activation of the
miR-17-92 promoter (Figure 4D). Collectively, these
results provide good evidence that c-Myc is critical for
the miR-17-92 cluster activation, and that GAM impairs
the miR-17-92 promoter activation by reducing, either
directly or indirectly, the positive transcriptional effects
of cMyc and those of unidentiﬁed factors acting on the
123-bp fragment lacking in Clu-3 construct or on se-
quences located upstream of Clu-2, at least in the condi-
tions of the experiment. Similar experiments showed that
GAM also impairs the activation of the miR-17-92 cluster
in HEK-293 and HepG2 cells (data not shown).
Of note, the activation of Clu-4 and Clu-5 following
GAM overexpression (Figure 4B), of Clu-5 following
c-Myc and/or GAM transfection (Figure 4C), of the
empty pGL3-Basic vector following siMyc transfection
(Figure 4D), as well as of Clu-3 and Clu-4 following
transfection with both siGAM and siMyc (Figure 4D)
most probably arose from off-target effects, known to
occur with the pGL3-Basic vector.
GAM and Drosha modulate each other’s levels
The differential effects of GAM on miR-17-92 miRNA
levels (Figures 3A–C, 6A and B and Supplementary
Figures S5 and S6) suggested that GAM may somehow
affect the processing of miR-17-92 primary RNAs. This
could possibly be done either by modulating, directly or
indirectly, the levels of Drosha or those of factors required
for the differential processing of miR-17-92 miRNAs, or
by interfering, directly or indirectly, with Drosha activity.
Interestingly, GAM overexpression in HEK-293 cells
decreased the levels of Drosha transcripts (Figure 5A)
and, as shown by reprobing the blots from Figure 2A
with an anti-Drosha antibody, of Drosha protein
(Figure 5B). Accordingly, siGAM lead to an increase
of both Drosha transcripts and Drosha protein levels
(Figure 5C and D). Of note, GAM overexpression did
Figure 4. GAM impairs the activation of the miR-17-92 promoter. (A) Schematic representation of the clones in pGL3-Basic containing different
parts of the genomic region upstream of the miR-17-92 cluster. The ﬁrst nucleotide of pre-miR-17 was arbitrarily used as nucleotide +1 for
convenience. The ends of the DNA fragments used to generate the Clu-1 to Clu-5 constructs are indicated. The positions of one c-Myc-binding
site (10) and of E2F-binding sites 1, 2 and 3, 4 (12) are indicated by an arrow. The approximate locations of TSS1 (transcription start site 1) (13) and
TSS2 (21) are indicated by arrowheads. (B and C) Effects of GAM on the miR-17-92 promoter either alone (B) or in conjunction with c-Myc (C).
MCF7 cells were transfected with the empty pGL3-Basic vector or the Clu-1 to Clu-5 constructs as indicated along with the empty pCMV-HA vector
or a construct expressing GAM and/or c-Myc. The Fireﬂy luciferase activity was measured 48h after transfection and then normalized to the Renilla
luciferase activity. Values represent the mean±SD (n=4). (D) Effects of siRNAs directed against GAM (siGAM) or against c-Myc transcripts
(siMyc) on the miR-17-92 promoter expression either alone or in conjunction. MCF7 cells were transfected with the empty pGL3-Basic vector or the
Clu-1 to Clu-4 constructs as indicated along with a control RNA, siGAM and/or siMyc. The Fireﬂy luciferase activity was measured 48h after
transfection and then normalized to the Renilla luciferase activity. Values represent the mean±SD (n=4).
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Drosha (Supplementary Figure S7). On the other hand,
transfecting the cells with siRNAs directed against Drosha
transcripts (siDrosha), which decreased Drosha transcripts
and Drosha protein levels by  60% (Supplementary
Figure S3E and F), showed to increase GAM transcripts
levels (Figure 5E), most probably by decreasing the levels
of several of the miRNAs potentially targeting GAM tran-
scripts. Thus, GAM and Drosha work within the same
gene regulatory network and control, directly or indirect-
ly, each other’s expression.
The fact that GAM downregulates Drosha suggested
that GAM may decrease the levels of most, if not all,
miRNAs by decreasing the processing of their primary
transcripts by Drosha. However, GAM overexpression in
HepG2 did not decrease the levels of either let-7d, let-7e or
let-7f and siGAM in contrast slightly but signiﬁcantly
downregulated let-7d (Figure 6E and F). This indicates
that the repressing effects of GAM are not global but
rather miRNA-speciﬁc. Accordingly, qRT–PCRs from
RNAs extracted of SW480 colon cells as well as micro-
arrays from RNAs prepared from THP-1 monocytic cells
showed that GAM can upregulate or downregulate some
miRNAs while leaving the levels of the others unchanged
(Tili et al., unpublished results). Thus, GAM-speciﬁc
effects on miRNA expression should require the
presence of speciﬁc trans-regulators of miRNA
processing. Finally, as siGAM did not increase Drosha
levels in HEK-293 cells by >30% (Figure 5D), and
given than Drosha is rather an abundant protein in
these cells, as shown by proteomic analyses (Tili et al.,
unpublished results), the differential downregulation of
miR-17-92 miRNAs by endogenous GAM cannot solely
come from its capability to downregulate Drosha, and
should also arise from GAM effects on at least some of
those unidentiﬁed factors regulating the differential pro-
cessing of miR-17-92 primary RNAs by Drosha.
GAM interacts with Drosha in a RNA-dependent manner
As GAM affected both the transcription and the process-
ing of miR-17-92 miRNAs, and given that these two
processes are generally coupled, we hypothesized that in
addition to modulating the expression of Drosha, GAM
may also possibly interfere with the processing of
pri-miRNA by Drosha. Furthermore, a massive yeast
two-hybrid screen suggested that GAM might directly
interact with Drosha (24). Indeed, a Flag-tagged full-size
Drosha allowed us to immunoprecipitate HA-tagged
full-size GAM in HEK-293 cells using an anti-Flag
antibody (Figure 5F). Accordingly, we were able to
immunoprecipitate endogenous Drosha along with
HA-GAM, conﬁrming that GAM and Drosha may
actually interact in vivo (Figure 5G). To gain further
insights into the possible consequences of GAM-Drosha
Figure 5. GAM downregulates Drosha, a critical effector of miRNA maturation, and GAM-Drosha interaction is RNA-dependent. (A and C)The
relative levels of Drosha transcripts in HEK-293 transfected with either the empty pCMV-HA vector or HA-GAM (A), or with either a Control RNA
or siGAM (C), were determined by qRT–PCR. Values represent the mean±SD (n=3). *P<0.05, signiﬁcantly different from control RNA. (B and
D) Drosha levels in extracts prepared from HEK-293 cells transfected with either the empty pCMV-HA vector or HA-GAM-2 (B), or with either a
Control RNA or siGAM (D), were analyzed by western blotting. The blots in B were from the same experiment as the blots of Figure 2A. (E) The
relative levels of GAM transcripts in HEK-293 transfected with either the Control RNA or siRNAs directed against Drosha transcripts (siDrosha)
were determined by qRT–PCR. Values represent the mean±SD (n=3). *P<0.001, signiﬁcantly different from Control RNA. (F–H) HEK-293 cells
were transfected with the empty pCMV-HA vector or pCMV-HA-GAM. In (F), cells were cotransfected with a Flag-Drosha construct. In (H),
extracts were submitted to RNase digestion before immunoprecipitation as indicated. Immunoprecipitations were conducted using anti-Flag (F) or
anti-HA antibody (G and H). Immunocomplexes were analyzed by western blotting with the indicated antibodies. In (G), the left blot (WCL) shows
the levels of endogenous Drosha in whole cell lysates of HEK-293 cells transfected as indicated, before immunoprecipitation (these blots were
prepared using 1/25th of the whole lysate subsequently used for immunoprecipitation).
Nucleic Acids Research, 2010,Vol.38, No. 21 7681Figure 6. GAM opposes the upregulation of miR-17-92 miRNAs by TGFb effectors. (A–C) HEK-293 (A and C) or HepG2 cells (B) were transfected
with either a control RNA or siGAM (A and B), or with the empty pCMV-HA vector or pCMV-HA-GAM (C). After 34h, they were either
mock-treated (A and B) or treated with TGFb (A–C) as indicated. The relative levels of the indicated miRNAs were determined by qRT–PCR.
Values represent the mean±SD (n=3). The results obtained with mock-treated samples (M) in (A) are the same as those in Figure 3B. They are
presented again along with the results obtained with TGFb-treated samples (Tb) for easier comparison, as they were drawn from the same experi-
ment. Panel A: * and **, siGAM signiﬁcantly different from Control RNA for each treatment, *, P<0.005, **, P<0.0005; #, TGFb-treated Control
RNA signiﬁcantly different from mock-treated Control RNA, P<0.0002; o and oo, TGFb-treated siGAM signiﬁcantly different from mock-treated
siGAM,o ,P<0.003, oo, P<0.0004. Panel B: * and **, siGAM signiﬁcantly different from Control RNA for each treatment, *, P<0.05, **,
P<0.002; #, TGFb-treated Control RNA signiﬁcantly different from mock-treated Control RNA, P<0.02; o and oo, TGFb-treated siGAM
signiﬁcantly different from mock-treated siGAM,o ,P<0.02, oo, P<0.01. Panel C: *, Signiﬁcantly different from Empty control vector,
P<0.05. (D) The relative levels of miR-17, miR-18a and miR-20a were determined by RNase-protection assays. Total RNAs extracted from
HepG2 cells (10mg per assay) treated and transfected as indicated (four left lanes) were hybridized with a radiolabelled RNA antisense probe
complementary to the indicated miRNAs. The lengths of the antisense miR-17, miR-18a and miR-20a probes were made equal to that of the
U6snRNA antisense probe by addition of a 30-poly(A)-tail. Namely, the RNases used in the assay (RNase 1 and RNase T1) are not able to cut
phosphodiester bonds following a non-paired A nt. The relative intensities of the protected fragments, given under each panel in percent of the
continued
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RNase A before immunoprecipitation. This reduced the
amount of endogenous Drosha interacting with GAM by
 50% (Figure 5H), indicating that Drosha-GAM inter-
actions take place when Drosha is engaged in pri-miRNA
processing. However, transfecting HEK-293 cells with
Clu-81 did not allow us to precipitate Drosha more efﬁ-
ciently than in presence of an empty control vector (results
not shown), suggesting that GAM differential effects on
miR-17-92 miRNAs processing require the presence of
other factors present in limiting amount, most probably
the very same factors responsible for the differential pro-
cessing of miR-17-92 miRNAs in untransfected cells (see
hereabove). This would also explain why GAM was never
reported to be part of the microprocessor complex.
Finally, whether GAM competes with some of these
miR-17-92 processing factors for binding to Drosha
and/or downregulates factors needed for the processing
of miRNAs such as miR-20a or miR-92a-1 remains to be
determined.
GAM opposes the upregulation of miR-17-92
miRNAs by TGFb
Usually, TGFb maintains tissue homeostasis and prevents
incipient tumor formation by regulating cellular prolifer-
ation, differentiation, survival and adhesion as well as the
cellular microenvironment. However, pathological forms
of TGFb signaling can promote tumor growth and
invasion, evasion of immune surveillance, cancer cell dis-
semination and metastasis (25). Importantly, miRNAs
have recently been shown to regulate the TGFb signaling
pathway. For example, the expression of miR-21 in breast
cancers predicts for elevated TGFb1 expression and a
poor clinical prognosis (26), while that in gliomas results
in the suppression of multiple components of the TGFb
signaling system, including its ligands (i.e. TGFbs 1 and
3), its receptors (i.e. TbR-II and TbR-III), and its effector
molecules (i.e. Smad3, Daxx, and PDCD4) (27,28).
Interestingly, the two-hybrid screen referred to here
above also showed that GAM may interact with Smad1
(an infrequent transducer of TGFb signaling), and that
siRNAs directed against GAM transcripts impaired the
upregulation of endogenous PAI-1 (Plasminogen
Activator Inhibitor-1) by TGFb (24). Therefore, as the
misexpression of miR-17-92 miRNAs has been associated
with cancers (5,9), we then looked for the effects of
TGFb1 (herafter referred to as TGFb)o nmiR-17-92
miRNA expression, and checked if these effects may be
affected by GAM levels.
TGFb increased the levels of miR-17-92 miRNAs in
HEK-293 (Figure 6A), HepG2 (Figure 6B) and MCF7
cells (Supplementary Figure S6). These levels generally
increased further when cells were transfected with
siGAM, indicating that GAM opposes the upregulation
of miR-17-92 miRNAs by TGFb. This was conﬁrmed by
the fact that GAM overexpression reduced the levels of
miR-17, 20a and -92a in HEK-293 cells treated with
TGFb (Figure 6C). Interestingly, the upregulation of
miR-17-92 miRNAs was not uniform, suggesting that
TGFb, as well as GAM, may somehow affect the matur-
ation of miR-17-92 miRNAs. The differential effects of
TGFb and siGAM on miR-17-92 miRNA expression
were further conﬁrmed in HepG2 cells by
RNase-protection assays using probes speciﬁc of miR-17,
-18a and -20a (Figure 6D). Together, these results show
that, in HEK-293, HepG2 and MCF7 cells, the differential
upregulation of miR-17-92 miRNAs by TGFb is differen-
tially buffered by endogenous GAM activity. Of note, the
upregulation of miR-17-92 miRNAs by TGFb effectors
was not due to its inhibition of the downregulation of
Drosha by endogenous GAM: namely, the TGFb treat-
ment did not signiﬁcantly affect Drosha transcripts nor
Drosha protein levels (Supplementary Figure S10). This
was further conﬁrmed by the fact that, while also
upregulating let-7e, TGFb did not change the levels of
let-7d or let-7f (Figure 6E and F). Thus, like those of
GAM, TGFb effects are miRNA-speciﬁc, and TGFb ef-
fectors most probably impact the levels of the same un-
identiﬁed regulators of miR-17-92 miRNA processing (see
hereabove).
Finally, siGAM also increased the levels of miR-106b
and -93 in MCF7 cells, with or without TGFb treatment
(Supplementary Figure S11), pointing to possible GAM
effects on the two miR-17-92 ortholog clusters.
GAM, miR-17-92a miRNAs and TGFb effectors work
within the same gene regulatory network
Beside reducing the translation of their target transcripts,
miRNAs also often drive their degradation (29).
Therefore, we then checked for possible effects of
miR-17-92 miRNAs on GAM transcript levels. In
HepG2 cells, pre-miR-17 downregulated GAM transcript
levels by 40% (Figure 7A). Of note, while pre-miR-20a
and -92a-1 reduced the levels of GAM transcripts by
 80%, their respective orthologs pre-miR-93 and -25 did
not, showing that miRNAs with comparable effects on
mRNA translation may well work differently on mRNA
stability (Figure 7A). In accordance with the fact that no
miR-18a target site is found in GAM transcripts,
pre-miR-18a did not affect GAM transcript levels. The
targeting of GAM transcripts by miR-17-92 miRNAs
was further conﬁrmed in HEK-293 cells overexpressing
Clu-81 (Figure 7C).
Figure 6. Continued
control sample (lane 1), were calculated using the U6snRNA as an internal control. The efﬁciency of RNase digestion was assessed in parallel
following the incubation of each probe with 10mg yeast tRNAs (two rights lanes). ‘-RNase’ controls correspond to a 15-fold dilution of the
undigested samples. Exposure time at  80 C was 36h for miR-17, miR-18a and miR-20a probes, and 2h for U6snRNA probe. Nd, non-digested,
Ns, non-speciﬁc. (E,F) HepG2 cells were transfected with either a pCMV-HA/Control RNA mix (Control), a pCMV-HA-GAM/Control RNA mix
(GAM) or a pCMV-HA/siGAM mix (siGAM). 34h later, they were either mock-treated or treated with TGFb. The relative levels of let-7d and let-7f
(E) and of let-7e (F) were determined by qRT–PCR. Values represent the mean±SD (n=3). Panel E: #, mock-treated siGAM signiﬁcantly different
from mock-treated Control, P=0.01; *, TGFb-treated siGAM signiﬁcantly different from mock-treated siGAM, P=0.03. Panel F: *, Signiﬁcantly
different from the corresponding mock-treated sample, *, P<0.02.
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miR-17-92 miRNAs on GAM expression. TGFb alone
reduced GAM transcript as well as GAM protein levels
(Figure 7A and B). A similar downregulation of GAM
transcript level by TGFb was also observed in HEK-293
(Figure 7D) and in MCF7 cells (Supplementary Figure
S12). Of note, transfecting HepG2 cells with either
pre-miR-17, -20a, -92a-1, -93 or -25 did not affect the
downregulation of GAM transcripts by TGFb (Figure
7A). This was probably due to the capability of TGFb
to upregulate endogenous miR-17-92 miRNAs, and
possibly also other miRNAs targeting GAM transcripts.
However, we do not rule out the possibility that TGFb
signaling may also trigger miRNA-independent repression
of GAM. Surprisingly, miR-18a impaired the
downregulation of GAM by TGFb (Figure 7A), possibly
by targeting SMAD2, a transducer of TGFb signaling
whose 30-UTR contains a miR-18 target site, and/or
some other repressors of GAM. Overall, these results
suggest that the downregulation of GAM by the effectors
of TGFb signaling is at least in part dependent of
miR-17-92 miRNA expression, and conversely that the
upregulation of miR-17-92 miRNAs by TGFb might
arise, at least in part, from its repressing effects on
GAM expression. Of note, the conjugate effects of GAM
and TGFb on miRNA expression also appear to be
miRNA-speciﬁc. Namely, TGFb unexpectedly impaired
the downregulation of let-7d by siGAM (Figure 6E), sug-
gesting that GAM and TGFb effectors, while having
opposite effects on miR-17-92 miRNA expression, may
work together to keep let-7d levels above a certain thresh-
old, in accordance with the fact that GAM and TGFb
were previously shown to collaborate and upregulate en-
dogenous PAI-1 (24).
Given the above interactions between GAM and TGFb
signaling, we further looked whether GAM may have
broader effects on TGFb canonical signaling pathway.
In this pathway, the active TGFb dimer signals by
bringing together two pairs of receptor serine/threonine
kinases known as the type I and type II receptors,
Figure 7. TGFb and miR-17-92 miRNAs downregulate GAM transcripts, while GAM impairs the canonical TGFb signaling pathway. (A) The levels
of GAM transcripts in HepG2 cells transfected with a pre-miR Control (Control) or the indicated pre-miRNAs, and either mock-treated or treated
with TGFb, were determined by qRT–PCR. Values represent the mean±SD calculated from triplicate qRT–PCR reactions of the same cDNAs. #,
TGFb-treated sample signiﬁcantly different from the corresponding mock-treated sample, P<0.003. * and **, Pre-miR mock-treated signiﬁcantly
different from mock-treated pre-miR Control, *, P<0.002, **, P<0.001. (B) GAM levels in Hep-G2 cells mock-treated or treated with TGFb were
analyzed by western blotting. (C,D) The relative levels of GAM transcripts in HEK-293 cells transfected with either the empty pCMV vector (Empty)
or Clu-81 (C), or either mock-treated or treated with TGFb (D) were determined by qRT–PCR. Values represent the mean±SD calculated from
three independent reverse transcription reactions, each analyzed by qRT–PCR in triplicates. Panel C: *, Signiﬁcantly different from Empty control
vector, P<0.001. Panel D: *, Signiﬁcantly different from mock-treatment, P<0.001. (E) After cotransfection with the SMAD2/SMAD3/SMAD4
luciferase reporter plasmid along with either a pCMV-HA/Control RNA mix, a pCMV-HA-GAM/Control RNA mix or a pCMV-HA/siGAM mix,
HepG2 cells were mock-treated or treated with TGFb. The Fireﬂy luciferase activity was measured 48h after transfection and then normalized to the
Renilla luciferase activity. Values represent the mean±SD (n=6). *, Signiﬁcantly different from Control, P<0.005. (F) The effects of GAM or
siGAM on p21/CDKN1A expression in HepG2 cells mock-treated or treated with TGFb were analyzed by western blotting.
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phosphorylate and activate the type I receptors that then
propagate the signal by phosphorylating SMAD tran-
scription factors, namely SMAD2 and SMAD3. Once
activated, SMAD2 and SMAD3 form a complex with
SMAD4, a binding partner common to all regulatory
SMADs (30), and then shuttle to the nucleus. While
GAM overexpression in HepG2 cells transfected with a
luciferase reporter construct containing SMAD2-4 respon-
sive elements remained without signiﬁcant effects, target-
ing endogenous GAM transcripts with siGAM increased
the luciferase activity by  60% (Figure 7E). Accordingly,
while GAM overexpression did not signiﬁcantly impair the
well established upregulation by TGFb of the cell-cycle
regulator p21/CDKN1A, siGAM lead to a 80% increase
of p21 level (Figure 7F). Thus, one possible way for GAM
to reduce the upregulation of miR-17-92 miRNAs by
TGFb may be to impair SMAD activity. Furthermore,
these results suggest that another important role for
GAM may be to lower the plateau of activation reached
by TGFb responsive genes under TGFb signaling.
Together, and taking also into account that miR-20a
has been shown to target TGFb type II receptors (22),
our results give strong evidence that GAM, miR-17-92
miRNAs and the effectors of the canonical TGFb signal-
ing pathway work within the same gene regulatory
network.
DISCUSSION
Our study provides the very ﬁrst data concerning the role
of GAM, a previously uncharacterized factor, in human
cells, in addition to shedding a new light on the regulation
and functions of miR-17-92 miRNAs. Altogether, our
results show that GAM is central to a gene regulatory
network, illustrated on the working model of Figure 8,
through which: (i) miR-17, -20a, -92a-1 and let-7
miRNAs reduce GAM expression by targeting GAM tran-
scripts; (ii) GAM downregulates miR-17-92 miRNAs both
by impairing the transcriptional activation of the
miR-17-92 cluster by c-Myc and by differentially affecting
the maturation of miR-17-92 miRNAs; (iii) GAM also
impairs the upregulation of miR-17-92 miRNAs by
TGFb effectors, possibly by decreasing the transcriptional
activity of SMADs following the activation of the TGFb
canonical pathway; (iv) GAM increases cell apoptosis
while reducing cell proliferation, and modulates, directly
or indirectly, the levels of E2F1 and Ras; and (v) GAM
decreases the levels of and interacts in a RNase-dependent
manner with Drosha, the main effector of miRNA matur-
ation in the nucleus.
Using synthetic pre-miRNAs as well as antisense inhibi-
tory RNAs for luciferase assays, qRT–PCRs and western
blotting analyses, we provided strong evidence that en-
dogenous miR-17-92 and let-7 miRNAs target GAM tran-
scripts. Importantly, our experiments also showed that,
while miR-17, miR-20a and miR-92a-1 work together to
downregulate GAM transcripts, miR-92a-1 upregulates
E2F1 in contrast to miR-17 and miR-20a.A smiR-92a-1
is the only miRNA of the cluster with orthologs in
non-vertebrates, it is possible that, following gene dupli-
cations in vertebrate lineage, evolution has kept the dif-
ferent miR-17-92 miRNAs in cluster to establish a yet
poorly understood mechanism of differential maturation,
thus allowing for the ﬁne tuning of their effects on their
hundreds of respective target genes.
Our promoter studies conﬁrmed the previously estab-
lished activating effects of c-Myc on the miR-17-92 cluster
(10), and showed that GAM limits, directly or indirectly,
c-Myc trancriptional activation of the miR-17-92 cluster
through TSS1 without affecting the levels of endogenous
c-Myc, although the mechanistic bases of GAM/c-Myc
interference remains to be elucidated. They revealed that
the miR-17-92 cluster constitutes a very complex transcrip-
tional unit with regulatory sequences spanning over
several thousands base pairs, from the site bound by
c-Myc just upstream of the TSS2 (10) to an upstream
123-bp fragment containing E2F1 sites 1 and 2 previously
shown to allow the transcriptional activation of the cluster
by E2F factors (12,13) to sequences located upstream of
the TSS1 and the 50-end of Clu-2 (this article). In any case,
it can be expected that the transcription of a cluster con-
taining miRNAs targeting key regulators of cell prolifer-
ation would be regulated in a number of different ways. Of
note, we have previously shown that chicken GAM inter-
acts with the heterogenous nuclear ribonucleoprotein U
(hnRNPU/SAF-A) (17), which is known to interact
with different transcription factors, including the gluco-
corticoid receptor, a member of the superfamily of
hormone nuclear receptors. Through this interaction,
hnRNPU represses glucocorticoid-induced activation by
sequestrating the glucocorticoid receptors on the nuclear
matrix (31). Further experiments would be required to
determine whether interacting with hnRNPU might
allow GAM to block the accession of c-Myc or other tran-
scriptional regulators to the miR-17-92 cluster promoter.
However, transcriptional regulation cannot explain why
each of the miR-17-92 miRNAs is processed differentially
within a certain type of cells based on qRT–PCRs and
RNase-protection assays. This form of differential
Figure 8. Working model depicting the intricate interaction loops
between GAM, TGFb effectors, Drosha, miR-17-92 and let-7
miRNAs. For clarity, only the main interactions have been represented.
Arrows indicate activating effects, and T-barred arrows inhibitory
effects. The effects of c-Myc on the miR-17-92 cluster were previously
described (10). See text for more details.
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certain degree in the different cell lines studied, which
suggests that it may represent a more general phenom-
enon. Namely, it was previously shown that miR-17-92
miRNA levels in mouse embryos are not uniform and
change differentially according to the stage of develop-
ment (32,33). Therefore, there is not much doubt that
these miRNAs are processed with a differential efﬁciency
from the miR-17-92 primary transcripts. Interestingly, the
relative levels of miR-20a and even more of miR-92a
remained consistently higher than those of the miRNAs
in a more 50-position, whether cells were submitted to the
different treatments, or not. One can hypothesize that the
differential processing of miR-17-92 miRNAs depends on
their relative position in the cluster. Addressing this
question will require to determine the levels of the differ-
ent miRNAs after shufﬂing their respective pre-miRNA
sequences within the expression constructs.
We further show that GAM and TGFb respectively
downregulates and upregulates miR-17-92 miRNAs in
HEK-293, HepG2 and MCF7 cells, and that GAM also
downregulates them in K562 lymphoid cells. In each case,
the above effects were miRNA-speciﬁc. This suggests that
GAM as well as TGFb effectors can modulate the levels of
the factors which control the speciﬁc processing of each of
miR-17-92 miRNAs. To date, nothing is known
about these regulators, except that hnRNPA1 is required
to allow the speciﬁc processing of miR-18a (19,20).
Nevertheless, the fact that miR-18a levels remained con-
sistently low in the different cell lines, with or without
treatment, indicate that these cells contain factors able
to speciﬁcally bias the processing of miR-17-92 primary
RNAs toward the production of miRNAs such as
miR-17, miR-20a and miR-92a-1. Furthermore,
overexpressing the whole miR-17-92 cluster using a high
expression pCMV vector did not change miR-17 expres-
sion, while increasing the levels of miR-20a and miR-92a
by no more than about 30 and 60%, respectively. This
suggests that the factors controlling the processing of
miR-17-92 primary transcripts by Drosha are present in
limiting amounts, thus precluding the in vitro analysis of
the consequences of GAM-Drosha interaction on the
activity of a puriﬁed Microprocessor complex following
GAM overexpression. Interestingly, GAM was previously
shown to interact not only with hnRNPU/SAF-A, but
also with hnRNP-M and Matrin 3, a component of the
nuclear matrix (17). As hnRNPU and hnRNP-M4 have
been found in the Microprocessor (34–36), and as
hnRNPU has also been shown to interact with Matrin 3
(37), this raises the question of whether GAM might
impair the access of Drosha to some of its target
pri-miRNAs by relocating it in speciﬁc domains of the
nuclear matrix.
Furthermore, while GAM downregulated both Drosha
and miR-17-92 miRNAs, TGFb signaling upregulated the
same miRNAs without changing Drosha levels. Of note,
the upregulation of miR-17-92 miRNAs by TGFb may
possibly help to understand how TGFb signaling can
promote tumor growth and metastasis (25), given that
miR-17-92 miRNAs tend to increase cell proliferation
and are usually considered as oncomiRs (5).
Furthermore, the effects of both GAM and TGFb effect-
ors were miRNA-speciﬁc. For example, TGFb
upregulated let-7e but did not change let-7d or let-7f
levels in HepG2 cells. On the other hand, while
overexpressing GAM or transfecting cells with siGAM
did not affect the levels of let-7e or let-7f miRNAs,
siGAM slightly but signiﬁcantly decreased let-7d levels,
an effect unexpectedly impaired by TGFb. Accordingly,
qRT–PCR experiments in SW480 cells as well as miRNA
microarrays in THP-1 monocytic cells showed that the
levels of a number of miRNAs remain unchanged follow-
ing transfection of these cells with either siGAM or a con-
struct overexpressing GAM, while other miRNAs are
either upregulated or downregulated (Tili et al., unpub-
lished results). Therefore, neither the downregulation of
Drosha by GAM nor GAM-Drosha interaction leads to
a general decrease of miRNA levels. Furthermore, neither
GAM nor TGFb exert global effects on the activity of the
miRNA processing machinery. In contrast, it is more
likely that the miRNA-speciﬁc effects of both GAM and
TGFb effectors may arise from their respective effects on
the expression and/or the activity of factors controlling
the processing of speciﬁc pri-miRNAs, especially that of
miR-17-92 primary transcripts. Of note, it has been previ-
ously shown that, depending on BMP or TGFb signaling,
SMAD1, SMAD5 or SMAD3 can control Drosha-
mediated miRNA maturation through their binding to
DEAD box RNA helicase p68 (27). It would thus be
very interesting to determine if SMAD2 and/or SMAD3
might similarly interfere with the processing of miR-17-92
pri-miRNAs by Drosha under TGFb signaling, and, if this
is the case, if GAM would be able to impair this inter-
action between SMAD2 or SMAD3 and Drosha.
However, while we were able to conﬁrm the previously
established GAM–SMAD1 interaction (24), we did not
found any GAM-SMAD2 or GAM–SMAD3 interaction
(Tili et al., unpublished results). Ultimately, elucidating
how the differential processing of miR-17-92 miRNAs is
controlled and identifying their key target transcripts may
be critical to understand the role of the miR-17-92 cluster
in tumor formation.
Importantly, in addition to opposing the upregulation
of miR-17-92 miRNAs by TGFb, GAM impaired the ac-
tivation of TGFb responsive genes, while TGFb in turn
downregulated GAM and GAM transcripts levels. This
suggests that GAM may be a bona ﬁde TGFb effector,
potentially implicated in many aspects of TGFb signaling.
It will thus be interesting to check whether GAM might
differentially affect the cytostatic and the pro-metastatic
activities of TGFb.
We also show that GAM modulates the levels of E2F1
and Ras at least in part through its repressing effects on
endogenous miR-92a-1, while increasing cell apoptosis
and reducing cell proliferation. The precise effects of
GAM on such complex phenotypes will not be easy to
determine. As GAM seems to regulate the levels of
many miRNAs, and in particular miRNAs which poten-
tially target hundreds of transcripts (e.g.  1.000 for
miR-17 and miR-20a, and  700 for miR-92a-1), GAM
activity is likely to affect cell homeostasis in a number
of different ways. Of note, it has also been shown that
7686 Nucleic Acids Research, 2010,Vol.38, No. 21TGFb1 can overcome Ras mitogenic effects (38–40), and
that Ras can counteract TGFb signaling by altering the
expression of TGFb type II receptor (41). It would thus
also be interesting to look whether GAM may play a role
in these reciprocal interactions. Finally, the available
public data show that GAM expression is higher in
brain, kidney and lung tumors but lower in breast,
colon, pancreas and prostate cancers, and that the expres-
sion of the miR-17-92 cluster negatively correlates with
that of GAM except in lung cells (http://www.cgl.ucsf.
edu/Research/genentech/gepis/index.html). Given the
above results, one can speculate that, while GAM has
not yet been connected to a particular pathology, GAM
misexpression may impair the proper balance between
pro- and anti-proliferation factors, thus increasing the
probability of tumor formation.
As a last remark, the emergence of the vertebrate
lineage coincided with successive gene duplications, the ap-
parition of new transcriptional regulators and new signal-
ing molecules, and the acquisition of new functionalities
such as a complex and more performing brain or
adaptative immunity. It is thus probable that the new
level of molecular complexity reached by vertebrates has
been made possible by the development of robust genetic
circuitries required to maintain cell homeostasis while
allowing the organism to dynamically respond to an ever
changing environment. Like GAM, TGFb as well as the
miR-17-92 cluster also appeared in vertebrates. It is there-
fore not surprising that they may be implicated in the
control of cell homostasis and interact with each other
in so many different ways. As GAM transcripts are poten-
tially targeted by  150 miRNAs, GAM is likely to par-
ticipate in feedback regulatory loops with many other
miRNAs.
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